Sort   by:  
 Page size 
Chronic antibody-mediated rejection (CAMR) represents the main cause of kidney graft loss, but its pathogenesis is unclear. In order to uncover the molecular mechanisms underlying this condition, we characterized the molecular signature of circulating peripheral blood mononuclear cells and, separate...
ORGANISM(S): Homo sapiens 
Chronic antibody-mediated rejection (CAMR) represents the main cause of kidney graft loss, but its pathogenesis is unclear. In order to uncover the molecular mechanisms underlying this condition, we characterized the molecular signature of circulating peripheral blood mononuclear cells and, separate...
ORGANISM(S): Homo sapiens 
Chronic antibody-mediated rejection (CAMR) represents the main cause of kidney graft loss, but its pathogenesis is unclear. In order to uncover the molecular mechanisms underlying this condition, we characterized the molecular signature of circulating peripheral blood mononuclear cells and, separate...
ORGANISM(S): Homo sapiens 
Histologic diagnosis of T cell-mediated rejection in kidney transplant biopsies has limited reproducibility because it is based on non-specific lesions using arbitrary rules that are subject to differing interpretations. We used microarray results from 403 indication biopsies previously given histol...
ORGANISM(S): Homo sapiens 
INTRODUCTION: Chronic antibody-mediated rejection (CAMR) is currently the leading cause of long-term allograft loss, affecting approximately 50-60% of renal transplant recipients after a decade. Although in the last years many studies have performed to define clinical/histological characteristics an...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD057746 | Pride
Transcriptomics of chronic antibody-mediated rejection
Single-cell Transcriptome Analysis of Chronic Antibody-mediated Rejection after Renal Transplantation
Histologic and molecular patterns in responders and non-responders with chronic-active antibody mediated rejection
Peripheral blood bulk RNA-seq validation cohort for chronic antibody-mediated rejection
Clazakizumab treatment effects on peripheral blood and kidney transcriptomes in chronic antibody-mediated rejection
Sort   by:  
 Page size